Published in Proc Natl Acad Sci U S A on August 23, 2010
Myalgic encephalomyelitis: International Consensus Criteria. J Intern Med (2011) 4.98
Recombinant origin of the retrovirus XMRV. Science (2011) 3.54
Disease-associated XMRV sequences are consistent with laboratory contamination. Retrovirology (2010) 2.90
Contamination of human DNA samples with mouse DNA can lead to false detection of XMRV-like sequences. Retrovirology (2010) 2.75
Mouse DNA contamination in human tissue tested for XMRV. Retrovirology (2010) 2.65
An endogenous murine leukemia viral genome contaminant in a commercial RT-PCR kit is amplified using standard primers for XMRV. Retrovirology (2010) 2.27
XMRV: a new virus in prostate cancer? Cancer Res (2010) 1.95
A cautionary tale of virus and disease. BMC Biol (2010) 1.93
Absence of XMRV retrovirus and other murine leukemia virus-related viruses in patients with chronic fatigue syndrome. J Virol (2011) 1.73
Structure of a conserved retroviral RNA packaging element by NMR spectroscopy and cryo-electron tomography. J Mol Biol (2010) 1.71
Failure to confirm XMRV/MLVs in the blood of patients with chronic fatigue syndrome: a multi-laboratory study. Science (2011) 1.56
DNA extraction columns contaminated with murine sequences. PLoS One (2011) 1.55
Contamination of clinical specimens with MLV-encoding nucleic acids: implications for XMRV and other candidate human retroviruses. Retrovirology (2010) 1.49
Serologic and PCR testing of persons with chronic fatigue syndrome in the United States shows no association with xenotropic or polytropic murine leukemia virus-related viruses. Retrovirology (2011) 1.42
The Blood Xenotropic Murine Leukemia Virus-Related Virus Scientific Research Working Group: mission, progress, and plans. Transfusion (2011) 1.41
PCR master mixes harbour murine DNA sequences. Caveat emptor! PLoS One (2011) 1.41
The mouse "xenotropic" gammaretroviruses and their XPR1 receptor. Retrovirology (2010) 1.35
In-depth investigation of archival and prospectively collected samples reveals no evidence for XMRV infection in prostate cancer. PLoS One (2012) 1.33
Benefit from B-lymphocyte depletion using the anti-CD20 antibody rituximab in chronic fatigue syndrome. A double-blind and placebo-controlled study. PLoS One (2011) 1.28
No evidence for XMRV in German CFS and MS patients with fatigue despite the ability of the virus to infect human blood cells in vitro. PLoS One (2010) 1.25
Phylogenetic analysis of murine leukemia virus sequences from longitudinally sampled chronic fatigue syndrome patients suggests PCR contamination rather than viral evolution. J Virol (2011) 1.23
No association of xenotropic murine leukemia virus-related virus with prostate cancer or chronic fatigue syndrome in Japan. Retrovirology (2011) 1.22
Analysis of XMRV integration sites from human prostate cancer tissues suggests PCR contamination rather than genuine human infection. Retrovirology (2011) 1.20
No association of xenotropic murine leukemia virus-related viruses with prostate cancer. PLoS One (2011) 1.19
No evidence of XMRV in prostate cancer cohorts in the Midwestern United States. Retrovirology (2011) 1.18
Insertional oncogenesis by non-acute retroviruses: implications for gene therapy. Viruses (2011) 1.09
Mouse retroviruses and chronic fatigue syndrome: Does X (or P) mark the spot? Proc Natl Acad Sci U S A (2010) 1.09
Evolution of functional and sequence variants of the mammalian XPR1 receptor for mouse xenotropic gammaretroviruses and the human-derived retrovirus XMRV. J Virol (2010) 1.08
XMRV and prostate cancer--a 'final' perspective. Nat Rev Urol (2012) 1.08
Frequent detection of infectious xenotropic murine leukemia virus (XMLV) in human cultures established from mouse xenografts. Cancer Biol Ther (2011) 1.06
Viral oncogenes, noncoding RNAs, and RNA splicing in human tumor viruses. Int J Biol Sci (2010) 1.05
No evidence of XMRV or related retroviruses in a London HIV-1-positive patient cohort. PLoS One (2011) 1.04
Investigation into the presence of and serological response to XMRV in CFS patients. PLoS One (2011) 1.01
The xenotropic murine leukemia virus-related retrovirus debate continues at first international workshop. Retrovirology (2010) 0.98
Recombinant origin, contamination, and de-discovery of XMRV. Curr Opin Virol (2012) 0.96
Xpr1 is an atypical G-protein-coupled receptor that mediates xenotropic and polytropic murine retrovirus neurotoxicity. J Virol (2011) 0.96
Infection of Xenotransplanted Human Cell Lines by Murine Retroviruses: A Lesson Brought Back to Light by XMRV. Front Oncol (2013) 0.95
Plasma neuropeptide Y: a biomarker for symptom severity in chronic fatigue syndrome. Behav Brain Funct (2010) 0.94
Restricted replication of xenotropic murine leukemia virus-related virus in pigtailed macaques. J Virol (2012) 0.93
Characterization, mapping, and distribution of the two XMRV parental proviruses. J Virol (2011) 0.93
EEG spectral coherence data distinguish chronic fatigue syndrome patients from healthy controls and depressed patients--a case control study. BMC Neurol (2011) 0.93
Unusual space-time patterning of the Fallon, Nevada leukemia cluster: Evidence of an infectious etiology. Chem Biol Interact (2011) 0.92
Evidence for a heritable predisposition to Chronic Fatigue Syndrome. BMC Neurol (2011) 0.90
Lack of infection with XMRV or other MLV-related viruses in blood, post-mortem brains and paternal gametes of autistic individuals. PLoS One (2011) 0.90
No detection of XMRV in blood samples and tissue sections from prostate cancer patients in Northern Europe. PLoS One (2011) 0.89
Chronic fatigue syndrome: xenotropic murine leukemia virus-related virus, murine leukemia virus, both, or neither? Proc Natl Acad Sci U S A (2010) 0.88
An unbiased metagenomic search for infectious agents using monozygotic twins discordant for chronic fatigue. BMC Microbiol (2011) 0.87
Nucleic Acid, Antibody, and Virus Culture Methods to Detect Xenotropic MLV-Related Virus in Human Blood Samples. Adv Virol (2011) 0.87
Melanoma, Darwinian medicine and the inner world. J Cancer Res Clin Oncol (2010) 0.85
No evidence for XMRV nucleic acids, infectious virus or anti-XMRV antibodies in Canadian patients with chronic fatigue syndrome. PLoS One (2011) 0.85
Murine gammaretrovirus group G3 was not found in Swedish patients with myalgic encephalomyelitis/chronic fatigue syndrome and fibromyalgia. PLoS One (2011) 0.84
No xenotropic murine leukemia virus-related virus detected in fibromyalgia patients. Emerg Infect Dis (2011) 0.84
No evidence for infection of UK prostate cancer patients with XMRV, BK virus, Trichomonas vaginalis or human papilloma viruses. PLoS One (2012) 0.83
Emerging infectious agents and the nation's blood supply: responding to potential threats in the 21st century. Transfusion (2012) 0.83
Phylogeny-directed search for murine leukemia virus-like retroviruses in vertebrate genomes and in patients suffering from myalgic encephalomyelitis/chronic fatigue syndrome and prostate cancer. Adv Virol (2011) 0.83
NF-kappaB activation stimulates transcription and replication of retrovirus XMRV in human B-lineage and prostate carcinoma cells. J Virol (2011) 0.83
Detection of murine leukemia virus or mouse DNA in commercial RT-PCR reagents and human DNAs. PLoS One (2011) 0.83
Failure to Detect XMRV-Specific Antibodies in the Plasma of CFS Patients Using Highly Sensitive Chemiluminescence Immunoassays. Adv Virol (2011) 0.82
No evidence of murine leukemia virus-related viruses in live attenuated human vaccines. PLoS One (2011) 0.82
No Evidence of XMRV or MuLV Sequences in Prostate Cancer, Diffuse Large B-Cell Lymphoma, or the UK Blood Donor Population. Adv Virol (2011) 0.82
Endogenous Murine Leukemia Viruses: Relationship to XMRV and Related Sequences Detected in Human DNA Samples. Adv Virol (2011) 0.82
Sensitivity of PCR assays for murine gammaretroviruses and mouse contamination in human blood samples. PLoS One (2012) 0.82
The left half of the XMRV retrovirus is present in an endogenous retrovirus of NIH/3T3 Swiss mouse cells. J Virol (2011) 0.81
Development and application of a high-throughput microneutralization assay: lack of xenotropic murine leukemia virus-related virus and/or murine leukemia virus detection in blood donors. Transfusion (2012) 0.81
No biological evidence of XMRV in blood or prostatic fluid from prostate cancer patients. PLoS One (2012) 0.81
Identification of a microRNA signature for the diagnosis of fibromyalgia. PLoS One (2015) 0.80
Antibody responses against xenotropic murine leukemia virus-related virus envelope in a murine model. PLoS One (2011) 0.80
Absence of XMRV in peripheral blood mononuclear cells of ARV-treatment naïve HIV-1 infected and HIV-1/HCV coinfected individuals and blood donors. PLoS One (2012) 0.80
Xenotropic murine leukemia virus-related virus is not associated with chronic fatigue syndrome in patients from different areas of the us in the 1990s. Virol J (2011) 0.80
An Etiological Model for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Neurosci Med (2011) 0.80
Lack of evidence for retroviral infections formerly related to chronic fatigue in Spanish fibromyalgia patients. Virol J (2013) 0.79
Xenotropic murine leukemia virus-related virus in monozygotic twins discordant for chronic fatigue syndrome. Diagn Microbiol Infect Dis (2011) 0.79
The saga of XMRV: a virus that infects human cells but is not a human virus. Emerg Microbes Infect (2014) 0.79
Xenotropic murine leukemia virus-related virus (XMRV) in patients with systemic lupus erythematosus. J Clin Immunol (2011) 0.79
Long-term infection and vertical transmission of a gammaretrovirus in a foreign host species. PLoS One (2012) 0.78
Development of sensitive single-round pol or env RT-PCR assays to screen for XMRV in multiple sample types. J Virol Methods (2011) 0.78
Susceptibility of human lymphoid tissue cultured ex vivo to xenotropic murine leukemia virus-related virus (XMRV) infection. PLoS One (2012) 0.78
No evidence for the involvement of XMRV or MCV in the pathogenesis of breast cancer. Br J Cancer (2012) 0.78
Xenotropic Murine Leukemia Virus-Related Virus (XMRV) and the Safety of the Blood Supply. Clin Microbiol Rev (2016) 0.77
Detecting retroviral sequences in chronic fatigue syndrome. Viruses (2010) 0.77
Of Mice and Men: On the Origin of XMRV. Front Microbiol (2011) 0.77
XMRV Discovery and Prostate Cancer-Related Research. Adv Virol (2011) 0.76
Absence of detectable XMRV and other MLV-related viruses in healthy blood donors in the United States. PLoS One (2011) 0.76
Partial molecular cloning of the JHK retrovirus using gammaretrovirus consensus PCR primers. Future Virol (2013) 0.75
Testing strategies for detection of xenotropic murine leukemia virus-related virus infection. Adv Virol (2011) 0.75
Patients, patience, and the publication process. Proc Natl Acad Sci U S A (2010) 0.75
No evidence of xenotropic murine leukaemia virus-related virus in French blood donors. Blood Transfus (2012) 0.75
Efficacy of rintatolimod in the treatment of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). Expert Rev Clin Pharmacol (2016) 0.75
No detection of the retrovirus xenotropic murine leukemia virus-related virus in individuals with hemophilia. Transfus Med Hemother (2013) 0.75
Possible widespread low-level occurrence of murine leukemia virus-related gene sequences in humans. Proc Natl Acad Sci U S A (2010) 0.75
XMRV and Public Health: The Retroviral Genome Is Not a Suitable Template for Diagnostic PCR, and Its Association with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Appears Unreliable. Front Public Health (2017) 0.75
The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med (1994) 26.24
Retracted Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome. Science (2009) 10.76
Retracted Identification of a novel Gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant. PLoS Pathog (2006) 10.08
Retracted XMRV is present in malignant prostatic epithelium and is associated with prostate cancer, especially high-grade tumors. Proc Natl Acad Sci U S A (2009) 6.72
Failure to detect the novel retrovirus XMRV in chronic fatigue syndrome. PLoS One (2010) 4.66
Nucleotide sequence of AKV murine leukemia virus. J Virol (1984) 4.58
Prevalence of human gammaretrovirus XMRV in sporadic prostate cancer. J Clin Virol (2008) 4.25
Absence of xenotropic murine leukaemia virus-related virus in UK patients with chronic fatigue syndrome. Retrovirology (2010) 4.18
Lack of evidence for xenotropic murine leukemia virus-related virus(XMRV) in German prostate cancer patients. Retrovirology (2009) 4.11
Absence of evidence of xenotropic murine leukemia virus-related virus infection in persons with chronic fatigue syndrome and healthy controls in the United States. Retrovirology (2010) 3.64
Human RNA "rumor" viruses: the search for novel human retroviruses in chronic disease. Microbiol Mol Biol Rev (2008) 3.07
Integration site preference of xenotropic murine leukemia virus-related virus, a new human retrovirus associated with prostate cancer. J Virol (2008) 2.83
The human retrovirus XMRV in prostate cancer and chronic fatigue syndrome. Nat Rev Urol (2010) 1.94
Molecular cloning, complete sequence, and biological characterization of a xenotropic murine leukemia virus constitutively released from the human B-lymphoblastoid cell line DG-75. Virology (2003) 1.77
A nonstructural gag-encoded glycoprotein precursor is necessary for efficient spreading and pathogenesis of murine leukemia viruses. J Virol (1994) 1.64
Virology. A new virus for old diseases? Science (2009) 1.38
Murine leukemia virus glycosylated Gag (gPr80gag) facilitates interferon-sensitive virus release through lipid rafts. Proc Natl Acad Sci U S A (2009) 1.18
Mutation in the glycosylated gag protein of murine leukemia virus results in reduced in vivo infectivity and a novel defect in viral budding or release. J Virol (2007) 1.18
Is human herpesvirus-6 a trigger for chronic fatigue syndrome? J Clin Virol (2006) 1.12
Functions of the 5' leader of murine leukemia virus genomic RNA in virion structure, viral replication and pathogenesis, and MLV-derived vectors. Biochimie (1996) 1.00
Absence of antibody to Mycoplasma fermentans in patients with chronic fatigue syndrome. Clin Infect Dis (1993) 0.94
Suppression of HCV-specific T cells without differential hierarchy demonstrated ex vivo in persistent HCV infection. Hepatology (2003) 2.45
Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis. Hepatology (2013) 2.17
Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. Proc Natl Acad Sci U S A (2002) 2.04
A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. Proc Natl Acad Sci U S A (2002) 2.02
Nuclear miRNA regulates the mitochondrial genome in the heart. Circ Res (2012) 1.95
Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralization. Proc Natl Acad Sci U S A (2008) 1.82
The latent human herpesvirus-6A genome specifically integrates in telomeres of human chromosomes in vivo and in vitro. Proc Natl Acad Sci U S A (2010) 1.82
Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activity. Proc Natl Acad Sci U S A (2009) 1.72
Hepatitis C virus epitope-specific neutralizing antibodies in Igs prepared from human plasma. Proc Natl Acad Sci U S A (2007) 1.66
Differential gene expression profiles are dependent upon method of peripheral blood collection and RNA isolation. BMC Genomics (2008) 1.65
Investigation of residual hepatitis C virus in presumed recovered subjects. Hepatology (2012) 1.61
Absence of transfusion-associated microchimerism in pediatric and adult recipients of leukoreduced and gamma-irradiated blood components. Transfusion (2011) 1.59
Failure to confirm XMRV/MLVs in the blood of patients with chronic fatigue syndrome: a multi-laboratory study. Science (2011) 1.56
A comparison of pregnancies that occur before and after the onset of chronic fatigue syndrome. Arch Intern Med (2004) 1.45
HCV natural history: the retrospective and prospective in perspective. J Hepatol (2005) 1.40
Influence of ethnicity in the outcome of hepatitis C virus infection and cellular immune response. Hepatology (2003) 1.39
Definition of APC presentation of phosphoantigen (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate to Vgamma2Vdelta 2 TCR. J Immunol (2008) 1.39
Human monoclonal antibodies that react with the E2 glycoprotein of hepatitis C virus and possess neutralizing activity. Hepatology (2005) 1.38
An assessment of hepatitis E virus (HEV) in US blood donors and recipients: no detectable HEV RNA in 1939 donors tested and no evidence for HEV transmission to 362 prospectively followed recipients. Transfusion (2013) 1.36
Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C. Gastroenterology (2003) 1.34
Molecular tracing of the global hepatitis C virus epidemic predicts regional patterns of hepatocellular carcinoma mortality. Gastroenterology (2006) 1.31
Immune gene networks of mycobacterial vaccine-elicited cellular responses and immunity. J Infect Dis (2006) 1.30
Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection. Proc Natl Acad Sci U S A (2003) 1.26
Phosphoantigen-activated V gamma 2V delta 2 T cells antagonize IL-2-induced CD4+CD25+Foxp3+ T regulatory cells in mycobacterial infection. Blood (2008) 1.25
Kaposi's sarcoma-associated herpesvirus ORF57 promotes escape of viral and human interleukin-6 from microRNA-mediated suppression. J Virol (2011) 1.25
A functional SNP of interferon-gamma gene is important for interferon-alpha-induced and spontaneous recovery from hepatitis C virus infection. Proc Natl Acad Sci U S A (2007) 1.24
Sodium/potassium ATPase (Na+, K+-ATPase) and ouabain/related cardiac glycosides: A new paradigm for development of anti- breast cancer drugs? Breast Cancer Res Treat (2005) 1.21
Frequency and duration of plasma CMV viremia in seroconverting blood donors and recipients. Transfusion (2003) 1.19
Investigation of SEN virus infection in patients with cryptogenic acute liver failure, hepatitis-associated aplastic anemia, or acute and chronic non-A-E hepatitis. J Infect Dis (2003) 1.18
Hepatitis C: the end of the beginning and possibly the beginning of the end. Ann Intern Med (2012) 1.18
A systems biology framework identifies molecular underpinnings of coronary heart disease. Arterioscler Thromb Vasc Biol (2013) 1.18
Highly quantitative serological detection of anti-cytomegalovirus (CMV) antibodies. Virol J (2009) 1.17
Effect of prenatal exposure to the endocrine disruptor bisphenol A on mammary gland morphology and gene expression signature. J Endocrinol (2008) 1.12
Evolution of hepatitis C viral quasispecies and hepatic injury in perinatally infected children followed prospectively. Proc Natl Acad Sci U S A (2006) 1.11
Genomic scale analysis of racial impact on response to IFN-alpha. Proc Natl Acad Sci U S A (2009) 1.08
Gene expression signatures of coronary heart disease. Arterioscler Thromb Vasc Biol (2013) 1.08
The concept of stem cell in the mammary gland and its implication in morphogenesis, cancer and prevention. Front Biosci (2006) 1.08
Review part 2: Human herpesvirus-6 in central nervous system diseases. J Med Virol (2010) 1.05
Antigen-specific Vgamma2Vdelta2 T effector cells confer homeostatic protection against pneumonic plaque lesions. Proc Natl Acad Sci U S A (2009) 1.05
Observation of positive selection within hypervariable regions of a newly identified DNA virus (SEN virus)(1). FEBS Lett (2002) 1.04
Strain-specific T-cell suppression and protective immunity in patients with chronic hepatitis C virus infection. J Virol (2005) 1.03
Phosphoantigen/IL2 expansion and differentiation of Vγ2Vδ2 T cells increase resistance to tuberculosis in nonhuman primates. PLoS Pathog (2013) 1.02
Power enhancement via multivariate outlier testing with gene expression arrays. Bioinformatics (2008) 1.02
Clinical spectrum and histopathologic features of chronic hepatitis C infection in children. J Pediatr (2007) 1.01
In Vitro and In Vivo studies of monoclonal antibodies with prominent bactericidal activity against Burkholderia pseudomallei and Burkholderia mallei. Clin Vaccine Immunol (2011) 1.01
Profibrogenic chemokines and viral evolution predict rapid progression of hepatitis C to cirrhosis. Proc Natl Acad Sci U S A (2012) 1.01
Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light. Transfusion (2005) 1.00
Mycoplasma fermentans infection promotes immortalization of human peripheral blood mononuclear cells in culture. Blood (2004) 0.98
SEN virus: epidemiology and characteristics of a transfusion-transmitted virus. Transfusion (2005) 0.97
Neutralization epitope responsible for the hepatitis B virus subtype-specific protection in chimpanzees. Proc Natl Acad Sci U S A (2006) 0.97
DR*W201/P65 tetramer visualization of epitope-specific CD4 T-cell during M. tuberculosis infection and its resting memory pool after BCG vaccination. PLoS One (2009) 0.96
Anti-viral state segregates two molecular phenotypes of pancreatic adenocarcinoma: potential relevance for adenoviral gene therapy. J Transl Med (2010) 0.96
TCR repertoire, clonal dominance, and pulmonary trafficking of mycobacterium-specific CD4+ and CD8+ T effector cells in immunity against tuberculosis. J Immunol (2010) 0.94
Isolation of novel Afipia septicemium and identification of previously unknown bacteria Bradyrhizobium sp. OHSU_III from blood of patients with poorly defined illnesses. PLoS One (2013) 0.94
The TOR complex 1 is distributed in endosomes and in retrograde vesicles that form from the vacuole membrane and plays an important role in the vacuole import and degradation pathway. J Biol Chem (2010) 0.94
Analysis of the functional integrity of cryopreserved human liver cells including xenografting in immunodeficient mice to address suitability for clinical applications. Liver Int (2004) 0.94
In utero exposure to butyl benzyl phthalate induces modifications in the morphology and the gene expression profile of the mammary gland: an experimental study in rats. Environ Health (2011) 0.94
SEN virus: response to interferon alfa and influence on the severity and treatment response of coexistent hepatitis C. Hepatology (2002) 0.93
EEG spectral coherence data distinguish chronic fatigue syndrome patients from healthy controls and depressed patients--a case control study. BMC Neurol (2011) 0.93
Review, part 1: Human herpesvirus-6-basic biology, diagnostic testing, and antiviral efficacy. J Med Virol (2010) 0.93
Evolutionary analysis of hepatitis C virus gene sequences from 1953. Philos Trans R Soc Lond B Biol Sci (2013) 0.92
NSOM- and AFM-based nanotechnology elucidates nano-structural and atomic-force features of a Y. pestis V immunogen-containing particle vaccine capable of eliciting robust response. Proteomics (2009) 0.91
Chronic fatigue syndrome: understanding a complex illness. Nat Rev Neurosci (2011) 0.91
Identification and characterization of EBV genomes in spontaneously immortalized human peripheral blood B lymphocytes by NGS technology. BMC Genomics (2013) 0.90
Enhanced hepatitis C virus NS3 specific Th1 immune responses induced by co-delivery of protein antigen and CpG with cationic liposomes. J Gen Virol (2004) 0.90
A 25-year study of the clinical and histologic outcomes of hepatitis C virus infection and its modes of transmission in a cohort of initially asymptomatic blood donors. J Infect Dis (2012) 0.90
Retraction for Lo et al., Detection of MLV-related virus gene sequences in blood of patients with chronic fatigue syndrome and healthy blood donors. Proc Natl Acad Sci U S A (2011) 0.90
Non-targeted identification of prions and amyloid-forming proteins from yeast and mammalian cells. J Biol Chem (2013) 0.89
Relationship between antigenicity and pathogenicity for Burkholderia pseudomallei and Burkholderia mallei revealed by a large panel of mouse MAbs. Hybridoma (Larchmt) (2008) 0.89
Development of real-time PCR array for simultaneous detection of eight human blood-borne viral pathogens. PLoS One (2012) 0.88
Association of interleukin-15-induced peripheral immune activation with hepatic stellate cell activation in persons coinfected with hepatitis C virus and HIV. J Infect Dis (2009) 0.88
Prospective study of hepatitis C viral infection as a risk factor for subsequent B-cell neoplasia. Blood (2002) 0.88
Review Part 3: Human herpesvirus-6 in multiple non-neurological diseases. J Med Virol (2010) 0.88
Parvovirus B19 infection transmitted by transfusion of red blood cells confirmed by molecular analysis of linked donor and recipient samples. Transfusion (2010) 0.88
Quantitative analysis of anti-hepatitis C virus antibody-secreting B cells in patients with chronic hepatitis C. Hepatology (2006) 0.87
Induction of potent cellular immune response in mice by hepatitis C virus NS3 protein with double-stranded RNA. Immunology (2007) 0.87
Modulation of cellular immune response against hepatitis C virus nonstructural protein 3 by cationic liposome encapsulated DNA immunization. Hepatology (2003) 0.86
The Vid vesicle to vacuole trafficking event requires components of the SNARE membrane fusion machinery. J Biol Chem (2003) 0.86
The clinical relevance of persistent recombinant immunoblot assay-indeterminate reactions: insights into the natural history of hepatitis C virus infection and implications for donor counseling. Transfusion (2012) 0.85
The plasticizer butyl benzyl phthalate induces genomic changes in rat mammary gland after neonatal/prepubertal exposure. BMC Genomics (2007) 0.85
Advances in developing molecular-diagnostic tools for strongyloid nematodes of equids: fundamental and applied implications. Mol Cell Probes (2004) 0.85
Identification of DNA signatures suitable for use in development of real-time PCR assays by whole-genome sequence approaches: use of Streptococcus pyogenes in a pilot study. J Clin Microbiol (2012) 0.84
Coadministration of cidofovir and smallpox vaccine reduced vaccination side effects but interfered with vaccine-elicited immune responses and immunity to monkeypox. J Virol (2008) 0.84